Aim Immunotech Inc (AIM) Stock Price, Quote & News

Company Profile

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the...

Industry: Biotechnology

Sector: Healthcare

Phone: 352 448 7797

Fax: 352 480 4620

Website: aimimmuno.com

Address:

2117 SW Highway 484, Ocala, United States

Jubileespirit Apr. 25 at 5:19 PM

$AIM sounds familiar.

0 · Reply

ultimatebastos Apr. 25 at 7:56 AM

$AIM the big bids… it’s no use there are to few shares on the market to solve your illegal shorting efforts.

0 · Reply

Jubileespirit Apr. 24 at 4:36 PM

$AIM over here! We’re over here!

0 · Reply

ultimatebastos Apr. 24 at 11:08 AM

$AIM the shorts have been robbing us 30+ years. I really think it’s going to end

1 · Reply

ultimatebastos Apr. 24 at 7:33 AM

$AIM the 30 years grand theft has to end one day…

0 · Reply

ultimatebastos Apr. 24 at 7:32 AM

$AIM it would be so cute to see the shorts burn like never before! Temperatures exceeding their wildest dreams.

0 · Reply

ultimatebastos Apr. 23 at 7:34 PM

$AIM yesterday shorted naked nearly 77 % Blatant criminal manipulation

0 · Reply

hitab Apr. 23 at 6:59 PM

$AIM i think they hope that the news on phase 2 in june will bring it back to 1.00

0 · Reply

hitab Apr. 23 at 6:59 PM

$AIM

0 · Reply

Kyle123 Apr. 23 at 6:06 PM

$AIM no curl yet but rise from the trend line no prediction but I’m watching closely. CTB still very high and no sign of significant covering. GLTA

0 · Reply

AIM ImmunoTech Transcript: Virtual Investor Closing Bell

Apr 13, 2026, 6:00 PM EDT - 12 days ago

AIM ImmunoTech Provides Routine Update on Annual Filings

Mar 18, 2026, 8:36 AM EDT - 5 weeks ago

AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors

Mar 6, 2026, 7:00 PM EST - 7 weeks ago

AIM ImmunoTech Announces Closing of its Rights Offering

Mar 2, 2026, 9:00 AM EST - 7 weeks ago

AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer

Feb 27, 2026, 9:00 AM EST - 2 months ago

AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering

Feb 23, 2026, 8:55 AM EST - 2 months ago

AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer

Feb 19, 2026, 4:00 PM EST - 2 months ago

AIM ImmunoTech Transcript: Virtual Investor Closing Bell

Feb 12, 2026, 4:35 PM EST - 2 months ago

CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering

Feb 11, 2026, 1:40 PM EST - 2 months ago

AIM ImmunoTech Transcript: Corporate Connect Webinar Series

Feb 11, 2026, 8:30 AM EST - 2 months ago

AIM ImmunoTech Announces Commencement of Rights Offering

Feb 6, 2026, 8:55 AM EST - 2 months ago

AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Feb 5, 2026, 8:40 AM EST - 2 months ago

AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

Jan 23, 2026, 1:22 PM EST - 3 months ago

AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering

Dec 16, 2025, 11:00 AM EST - 4 months ago

AIM ImmunoTech Transcript: AGM 2025

Dec 4, 2025, 4:00 PM EST - 5 months ago

AIM ImmunoTech Transcript: Virtual Investor Closing Bell Series

Dec 1, 2025, 8:55 AM EST - 5 months ago

AIM ImmunoTech to Participate in Live ‘Fireside' Chat on Virtual Investor Closing Bell Series

Nov 18, 2025, 8:55 AM EST - 5 months ago

AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program

Nov 10, 2025, 8:55 AM EST - 5 months ago

AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer

Nov 4, 2025, 9:05 AM EST - 6 months ago

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

Oct 20, 2025, 9:15 AM EDT - 6 months ago

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

Sep 25, 2025, 8:45 AM EDT - 7 months ago

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

Sep 4, 2025, 11:00 AM EDT - 8 months ago

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

Aug 21, 2025, 9:00 AM EDT - 8 months ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Aug 15, 2025, 9:00 AM EDT - 9 months ago

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 8:55 AM EDT - 9 months ago

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 6, 2025, 9:00 AM EDT - 9 months ago

AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

Aug 4, 2025, 9:00 AM EDT - 9 months ago

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

Jul 28, 2025, 11:12 AM EDT - 9 months ago

Why Is Micro-Cap AIM ImmunoTech Stock Surging?

Jul 2, 2025, 8:55 AM EDT - 10 months ago

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

Jun 20, 2025, 4:15 PM EDT - 11 months ago

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements

Jun 17, 2025, 8:55 AM EDT - 11 months ago

AIM ImmunoTech Resumes Trading on NYSE American

Jun 12, 2025, 8:30 AM EDT - 11 months ago

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

Jun 12, 2025, 8:00 AM EDT - 11 months ago

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension

Jun 11, 2025, 4:15 PM EDT - 11 months ago

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

May 8, 2025, 8:45 AM EDT - 1 year ago

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

Apr 7, 2025, 1:26 PM EDT - 1 year ago

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

Apr 4, 2025, 4:45 PM EDT - 1 year ago

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

Apr 4, 2025, 4:05 PM EDT - 1 year ago

NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM)

Apr 1, 2025, 8:30 AM EDT - 1 year ago

AIM ImmunoTech Earnings Call Transcript: Q4 2024

Mar 11, 2025, 8:45 AM EDT - 1 year ago

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 28, 2025, 8:45 AM EST - 1 year ago

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

Feb 26, 2025, 1:20 PM EST - 1 year ago

AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Feb 26, 2025, 8:30 AM EST - 1 year ago

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

Feb 25, 2025, 8:30 AM EST - 1 year ago

AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

Feb 11, 2025, 8:45 AM EST - 1 year ago

AIM ImmunoTech Releases Virtual Investor “What This Means Segment”

Feb 11, 2025, 8:30 AM EST - 1 year ago

AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024

Feb 7, 2025, 8:50 AM EST - 1 year ago

AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks

Jan 23, 2025, 8:50 AM EST - 1 year ago

AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions

Jan 22, 2025, 8:30 AM EST - 1 year ago

AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS

Jan 15, 2025, 9:05 AM EST - 1 year ago

AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones

Dec 17, 2024, 4:45 PM EST - 1 year ago

AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Dec 17, 2024, 3:10 PM EST - 1 year ago

AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting

Dec 16, 2024, 8:00 AM EST - 1 year ago

AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card

Dec 14, 2024, 4:54 PM EST - 1 year ago

Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board

Dec 12, 2024, 3:00 PM EST - 1 year ago

AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members

Nov 15, 2024, 8:30 AM EST - 1 year ago

AIM ImmunoTech Earnings Call Transcript: Q3 2024

Oct 16, 2024, 12:30 PM EDT - 1 year ago

AIM ImmunoTech Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Aug 16, 2024, 8:30 AM EDT - 1 year ago

AIM ImmunoTech Earnings Call Transcript: Q2 2024

May 16, 2024, 8:30 AM EDT - 2 years ago

AIM ImmunoTech Earnings Call Transcript: Q1 2024

Apr 2, 2024, 8:30 AM EDT - 2 years ago

AIM ImmunoTech Earnings Call Transcript: Q4 2023

Mar 20, 2024, 12:00 PM EDT - 2 years ago

AIM ImmunoTech Transcript: Fireside Chat

Nov 15, 2023, 8:30 AM EST - 2 years ago

AIM ImmunoTech Earnings Call Transcript: Q3 2023

Aug 15, 2023, 8:30 AM EDT - 2 years ago

AIM ImmunoTech Earnings Call Transcript: Q2 2023

May 16, 2023, 8:30 AM EDT - 3 years ago

AIM ImmunoTech Earnings Call Transcript: Q1 2023

Apr 3, 2023, 8:30 AM EDT - 3 years ago

AIM ImmunoTech Earnings Call Transcript: Q4 2022

Jubileespirit Apr. 25 at 5:19 PM

$AIM sounds familiar.

0 · Reply

ultimatebastos Apr. 25 at 7:56 AM

$AIM the big bids… it’s no use there are to few shares on the market to solve your illegal shorting efforts.

0 · Reply

Jubileespirit Apr. 24 at 4:36 PM

$AIM over here! We’re over here!

0 · Reply

ultimatebastos Apr. 24 at 11:08 AM

$AIM the shorts have been robbing us 30+ years. I really think it’s going to end

1 · Reply

ultimatebastos Apr. 24 at 7:33 AM

$AIM the 30 years grand theft has to end one day…

0 · Reply

ultimatebastos Apr. 24 at 7:32 AM

$AIM it would be so cute to see the shorts burn like never before! Temperatures exceeding their wildest dreams.

0 · Reply

ultimatebastos Apr. 23 at 7:34 PM

$AIM yesterday shorted naked nearly 77 % Blatant criminal manipulation

0 · Reply

hitab Apr. 23 at 6:59 PM

$AIM i think they hope that the news on phase 2 in june will bring it back to 1.00

0 · Reply

hitab Apr. 23 at 6:59 PM

$AIM

0 · Reply

Kyle123 Apr. 23 at 6:06 PM

$AIM no curl yet but rise from the trend line no prediction but I’m watching closely. CTB still very high and no sign of significant covering. GLTA

0 · Reply

jonjonson1234 Apr. 23 at 4:26 PM

I think that there is a better-than-even chance that we will see a reverse-split from $AIM in 2026. What do others think the odds are?

3 · Reply

Snorken Apr. 23 at 10:03 AM

$AIM https://www.biospace.com/business/japanese-pharmas-looking-beyond-borders-for-m-a-to-us-eu

0 · Reply

ReversedRunners Apr. 23 at 1:21 AM

$AIM need more news

0 · Reply

MRVivke Apr. 22 at 1:06 PM

$AIM 10× easy and thats without a buyout. Patience Grasshopper

1 · Reply

ultimatebastos Apr. 21 at 2:20 PM

$AIM yesterday shorted naked 63.28% that is humongous desperation again and totally unsustainable for what they did to keep it down…

1 · Reply

TheLionofwallstreet Apr. 20 at 10:04 PM

$AIM ssr release the kraken already lmao

0 · Reply

ultimatebastos Apr. 20 at 8:30 PM

$AIM the naked shorts are still shorting 40 to 60% daily while there is nearly no free float. They will burst one of these days….

0 · Reply

FeliciaMath Apr. 20 at 6:26 PM

sold $AIM at .50. lost $214/11%

0 · Reply

UncleAlbie Apr. 20 at 6:14 PM

$AIM Florida just called, they want your entrepreneur of the year award back, so they can give it to someone more deserving.! Nice job Tom

2 · Reply

rayk1 Apr. 20 at 6:09 PM

$AIM NEW ALL TIME LOW!!!! Congrats Eauels for the new record👍 You deserve a new “Entrepreneur of the year“ award for sure!! 😂👍🤮

0 · Reply

jonjonson1234 Apr. 20 at 3:02 PM

$AIM The first quarter 10-Q will probably be out on May 15th. It will be interesting to see the latest number on Stockholders' Equity. Remember, if they do not get stockholders' equity above +$6 million by June 11th, 2026, they will be delisted. The trend has not been encouraging so far. June 11, 2026 is just 52 days away... From prior filings: Date Stockholders' Equity 12/31/24 - $1.3 million 3/31/25 -$ 3.857 million 6/30/25 -$6.546 million 9/30/25 -$6.077 million 12/31/25 -$9.783 million

1 · Reply

ultimatebastos Apr. 20 at 2:47 PM

$AIM naked shorting criminals get in trouble and then they short more naked….

0 · Reply

Market Cap	4.24M
Revenue (ttm)	90,000.00
Net Income (ttm)	-13.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-15,511.11%
Debt to Equity Ratio	-0.10

Volume	98,100
Avg Vol	4,214,386
Day's Range	N/A - N/A
Shares Out	8.15M
Stochastic %K	32%
Beta	1.36
Analysts	Sell
Price Target	$14.00